干细胞治疗硬皮病研究进展

doi:10.16138/j.1673-6087.2025.04.15

摘要/Abstract

摘要：

硬皮病是一种以皮肤及内脏组织纤维化为主要特征的自身免疫性结缔组织病，目前尚缺乏满意的治疗方法。近年来，干细胞因其自我更新和多向分化潜能，已成为治疗多种疾病的新兴手段，在硬皮病治疗领域也取得显著进展。本文综述了近年来干细胞治疗硬皮病的机制及临床研究进展，以期为未来基础研究提供新思路，并为临床治疗提供理论依据。

关键词: 硬皮病, 造血干细胞移植, 间充质干细胞移植

Abstract:

Scleroderma is an autoimmune connective tissue disorder characterized by fibrosis of the skin and internal organs. Currently, there is no fully satisfactory treatment for this condition. In recent years, stem cells have emerged as a promising therapeutic strategy for a variety of diseases, owing to their capacities for self-renewal and multilineage differentiation. Substantial advances have been achieved in applying stem cell therapy to scleroderma. This review summarizes the mechanisms and clinical progress of stem cell-based treatments for scleroderma, with the aim of providing new insights for basic research and supporting evidence for future clinical applications.

Key words: Scleroderma, Hematopoietic stem cell transplantation, Mesenchymal stem cell transplantation

中图分类号:

R593.25

林瑞莲, 马丽丽, 陈佳. 干细胞治疗硬皮病研究进展[J]. 内科理论与实践, 2025, 20(04): 340-344.

LIN Ruilian, MA Lili, CHEN Jia. Advances in stem cell therapy for scleroderma[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(04): 340-344.

参考文献 43

[1]	Teske N, Fett N. Recent advances in treatment of systemic sclerosis and morphea[J]. Am J Clin Dermatol, 2024, 25(2):213-226. doi: 10.1007/s40257-023-00831-2 pmid: 38087156
[2]	Jerjen R, Nikpour M, Krieg T, et al. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2022, 87(5):937-954. doi: 10.1016/j.jaad.2021.10.065 pmid: 35131402
[3]	Papara C, De Luca DA, Bieber K, et al. Morphea: the 2023 update[J]. Front Med, 2023, 10:1108623.
[4]	Jessop H, Farge D, Saccardi R, et al. General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs)[J]. Bone Marrow Transplant, 2019, 54(7):933-942.
[5]	Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated Guidelines of the European Group for Blood and Marrow Transplant[J]. Bone Marrow Transplant, 2012, 47(6):770-790.
[6]	Levin D, Hakim A, Shezen E, et al. Hematopoietic stem cell transplantation for systemic sclerosis: mechanisms of immune reconstitution and disease reset[J]. Cells, 2022, 11(19):3075.
[7]	Kobayashi S, Nagafuchi Y, Shoda H, et al. The pathophysiological roles of regulatory T cells in the early phase of systemic sclerosis[J]. Front Immunol, 2022, 13:900638.
[8]	Baraut J, Grigore EI, Jean-Louis F, et al. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT[J]. Bone Marrow Transplant, 2014, 49(3):349-354.
[9]	Lima-Júnior JR, Arruda LCM, Gonçalves MS, et al. Autologous haematopoietic stem cell transplant restores the suppressive capacity of regulatory B cells in systemic sclerosis patients[J]. Rheumatology, 2021, 60(12):5538-5548. doi: 10.1093/rheumatology/keab257 pmid: 33724344
[10]	Adamska JZ, Zia A, Bloom MS, et al. Myeloablative autologous haematopoietic stem cell transplant resets the B cell repertoire to a more naïve state in patients with systemic sclerosis[J]. Ann Rheum Dis, 2023, 82(3):357-364.
[11]	Ayoglu B, Donato M, Furst DE, et al. Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplant[J]. Ann Rheum Dis, 2023, 82(5):670-680. doi: 10.1136/ard-2021-221926 pmid: 36653124
[12]	Wareing N, Wang X, Keyes-Elstein L, et al. Myeloablation followed by hematopoietic stem cell transplant and long-term normalization of systemic sclerosis molecular signatures[J]. Arthritis Rheumatol, 2024, 76(8):1288-1293.
[13]	Tyndall A, Black C, Finke J, et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation[J]. Lancet, 1997, 349(9047):254. pmid: 9014919
[14]	Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST)[J]. Lancet, 2011, 378(9790):498-506.
[15]	van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis[J]. JAMA, 2014, 311(24):2490-2498.
[16]	Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma[J]. N Engl J Med, 2018, 378(1):35-47.
[17]	Higashitani K, Takase-Minegishi K, Yoshimi R, et al. Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis[J]. Mod Rheumatol, 2023, 33(2):330-337.
[18]	van Bijnen S, de Vries-Bouwstra J, van Den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis[J]. Ann Rheum Dis, 2020, 79(8):1084-1089.
[19]	Franks JM, Martyanov V, Wang Y, et al. Machine learning predicts stem cell transplant response in severe scleroderma[J]. Ann Rheum Dis, 2020, 79(12):1608-1615. doi: 10.1136/annrheumdis-2020-217033 pmid: 32933919
[20]	Ayano M, Tsukamoto H, Mitoma H, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis[J]. Arthritis Res Ther, 2019, 21(1):30.
[21]	Bruera S, Sidanmat H, Molony DA, et al. Stem cell transplantation for systemic sclerosis[J]. Cochrane Database Syst Rev, 2022, 7(7):CD011819.
[22]	Moll M, Holzer U, Zimmer C, et al. Autologous stem cell transplantation in two children with disabling pansclerotic morphea[J]. Pediatr Rheumatol Online J, 2011, 9 Suppl 1:P77.
[23]	Nair V, Sharma A, Sharma S, et al. Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma[J]. Int J Rheum Dis, 2015, 18(3):366-371. doi: 10.1111/1756-185X.12555 pmid: 25923607
[24]	Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications[J]. Int J Mol Sci, 2022, 23(17):10023.
[25]	Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells[J]. Cytotherapy, 2019, 21(10):1019-1024. doi: S1465-3249(19)30841-2 pmid: 31526643
[26]	Guiducci S, Manetti M, Romano E, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro[J]. Ann Rheum Dis, 2011, 70(11):2011-2021. doi: 10.1136/ard.2011.150607 pmid: 21821866
[27]	Griffin M, Ryan CM, Pathan O, et al. Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls[J]. Stem Cell Res Ther, 2017, 8(1):23.
[28]	Müller L, Tunger A, Wobus M, et al. Immunomodulatory properties of mesenchymal stromal cells[J]. Front Cell Dev Biol, 2021, 9:637725.
[29]	Dudek DW, Walczuk E, Wajda A, et al. Mesenchymal stem cells in systemic sclerosis therapy[J]. Reumatologia, 2020, 58(5):324-330.
[30]	Sensebé L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells[J]. Hum Gene Ther, 2011, 22(1):19-26. doi: 10.1089/hum.2010.197 pmid: 21028982
[31]	Christopeit M, Schendel M, Föll J, et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L[J]. Leukemia, 2008, 22(5):1062-1064. doi: 10.1038/sj.leu.2404996 pmid: 17972956
[32]	Keyszer G, Christopeit M, Fick S, et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five cases[J]. Arthritis Rheum, 2011, 63(8):2540-2542.
[33]	Guiducci S, Porta F, Saccardi R, et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis[J]. Ann Intern Med, 2010, 153(10):650-654. doi: 10.7326/0003-4819-153-10-201011160-00007 pmid: 21079220
[34]	Farge D, Loisel S, Resche-Rigon M, et al. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis[J]. Lancet Rheumatol, 2022, 4(2):e91-e104.
[35]	Scuderi N, Ceccarelli S, Onesti MG, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis[J]. Cell Transplant, 2013, 22(5):779-795. pmid: 22526170
[36]	Ménard C, Dulong J, Roulois D, et al. Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells[J]. Stem Cells, 2020, 38(1):146-159. doi: 10.1002/stem.3077 pmid: 31502731
[37]	Granel B, Daumas A, Jouve E, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis[J]. Ann Rheum Dis, 2015, 74(12):2175-2182.
[38]	Daumas A, Magalon J, Jouve E, et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis[J]. Rheumatology, 2022, 61(5):1936-1947.
[39]	Liu J, Wang J, Zhang Q, et al. Clinical, histologic, and transcriptomic evaluation of sequential fat grafting for morphea[J]. JAMA Dermatol, 2024, 160(4):425-433.
[40]	Barrett AN, Fong CY, Subramanian A, et al. Human Wharton’s jelly mesenchymal stem cells show unique gene expression compared with bone marrow mesenchymal stem cells using single-cell RNA-sequencing[J]. Stem Cells Dev, 2019, 28(3):196-211. doi: 10.1089/scd.2018.0132 pmid: 30484393
[41]	Zhang H, Liang J, Tang X, et al. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis[J]. Arthritis Res Ther, 2017, 19(1):165. doi: 10.1186/s13075-017-1373-2 pmid: 28724445
[42]	Liang J, Zhang H, Kong W, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cell infusion[J]. Stem Cell Res Ther, 2018, 9(1):312. doi: 10.1186/s13287-018-1053-4 pmid: 30428931
[43]	Wang L, Li T, Ma X, et al. Exosomes from human adipose-derived mesenchymal stem cells attenuate localized scleroderma fibrosis by the Let-7a-5p/TGF-βR1/Smad axis[J]. J Dermatol Sci, 2023, 112(1):31-38. doi: 10.1016/j.jdermsci.2023.09.001 pmid: 37743142